Am J Transplant. 2010 Jul;10(7):1701-6.

Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?

Canaud G, Knebelmann B, Harris PC, Vrtovsnik F, Correas JM, Pallet N, Heyer CM, Letavernier E, Bienaimé F, Thervet E, Martinez F, Terzi F, Legendre C.

Source

INSERM U, Centre de Recherche Croissance et Signalisation, Hôpital Necker Rue de Sèvres, Paris, France. guillaume.canaud@nck.aphp.fr

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disease, and sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to significantly retard cyst expansion in animal models. The optimal therapeutic dose of sirolimus is not yet defined. Here, we report the history of a previously unknown ADPKD deceased donor whose kidneys were engrafted in two different recipients. One of the two received an immunosuppressive regimen based on sirolimus for 5 years while the other did not. After transplantation, both patients developed severe transplant cystic disease. Donor DNA sequence identified a new hypomorphic mutation in PKD1. The rate of cyst growth was identical in the two patients regardless of the treatment. While sirolimus treatment reduced the activation of mTOR in peripheral blood mononuclear cells, it failed to prevent mTOR activation in kidney tubular cells, this could account for the inefficiency of treatment on cyst growth. Together, our results suggest that the dose of sirolimus required to inhibit mTOR varies according to the tissue.

PMID:: 20642692; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

Case Reports

MeSH Terms

Substances

Grant Support

R01 DK058816-11/DK/NIDDK NIH HHS/United States

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Molecular Biology Databases

SIROLIMUS - HSDB

Supplemental Content

Save items

Related citations in PubMed

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. [N Engl J Med. 2010]
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, et al. N Engl J Med. 2010 Aug 26; 363(9):820-9. Epub 2010 Jun 26.
Everolimus in patients with autosomal dominant polycystic kidney disease. [N Engl J Med. 2010]
Everolimus in patients with autosomal dominant polycystic kidney disease.
Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, et al. N Engl J Med. 2010 Aug 26; 363(9):830-40. Epub 2010 Jun 26.
Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). [Nephrol Dial Transplant. 2006]
Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP. Nephrol Dial Transplant. 2006 Mar; 21(3):598-604. Epub 2005 Oct 12.
Review Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease. [Transplant Proc. 2010]
Review Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Wüthrich RP, Kistler AD, Serra AL. Transplant Proc. 2010 Nov; 42(9 Suppl):S44-6.
Review [Autosomal dominant polycystic kidney disease (ADPKD): rapamycin as a new treatment option]. [Praxis (Bern 1994). 2009]
Review [Autosomal dominant polycystic kidney disease (ADPKD): rapamycin as a new treatment option].
Serra AL, Wüthrich RP. Praxis (Bern 1994). 2009 Dec 16; 98(25):1511-6.

See reviews... See all...

Cited by 1 PubMed Central article

Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling. [FASEB J. 2011]
Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling.
Lisse TS, Liu T, Irmler M, Beckers J, Chen H, Adams JS, Hewison M. FASEB J. 2011 Mar; 25(3):937-47. Epub 2010 Dec 1.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: Wha...
Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?
Am J Transplant. 2010 Jul ;10(7):1701-6.

PubMed
Anesthetic management in a child with Angelman syndrome.
Anesthetic management in a child with Angelman syndrome.
Paediatr Anaesth. 2010 Jul ;20(7):675-6.

PubMed
European Federation of Neurological Societies/Peripheral Nerve Society Guideline...
European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.
Eur J Neurol. 2010 Jul ;17(7):903-12, e44-9.

PubMed
Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and ...
Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.
Br J Clin Pharmacol. 2010 Jul ;70(1):78-87.

PubMed
Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl pe...
Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
Br J Clin Pharmacol. 2010 Jul ;70(1):34-42.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: